Company Profile

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Employees

Sector

Biotechnology & Medical Research

More about the company

20-07-02	Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Biotechnology Select Industry Index	CI
20-07-02	Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P TMI Index	CI
20-07-02	Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Global BMI Index	CI
20-06-30	Alexion Pharmaceuticals, Inc. completed the acquisition of the remaining 96.6% stake in Portola Pharmaceuticals, Inc..	CI
20-06-17	Portola Pharmaceuticals, Inc. Receives Written Notice of Termination from Bayer AG	CI
20-05-11	Portola Pharmaceuticals, Inc. Suspends Prior Guidance for Approximately 350 New Hospital Adds in 2020	CI
20-05-11	Portola Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-05-04	Alexion Pharmaceuticals, Inc. entered into non-binding expression of interest to acquire remaining 96.6% stake in Portola Pharmaceuticals, Inc. for $1.4 billion.	CI
20-04-09	Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer, Inc. Aggress to Terminate the Collaboration and License Agreement Among the Parties	CI
20-04-07	Portola Pharmaceuticals, Inc. Announces the Establishment of Permanent J-Code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020	CI
20-03-16	Portola Pharmaceuticals, Inc. Announces Results Demonstrating Andexxa® Was Associated with Low Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds	CI
20-03-05	New Data Demonstrates Andexxa Can Provide Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors	CI
20-02-26	Portola Pharmaceuticals, Inc., Q4 2019 Earnings Call, Feb 26, 2020

20-07-02	PORTOLA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
20-06-30	Portola Pharmaceuticals : Amendment to a previously filed SC TO-T	PU
20-06-30	Portola Pharmaceuticals : Amendment to a previously filed SC 14D9	PU
20-06-17	PORTOLA PHARMACEUTICALS INC : Other Events (form 8-K)	AQ
20-06-15	PORTOLA PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PORTOLA PHARMACEUTICALS, INC.	-.--%	+0.45%	-	-	1.42B
LONZA GROUP AG	+0.27%	-0.23%	-18.25%	-17.11%	43.3B
BEONE MEDICINES AG	+1.39%	+6.03%	+35.81%	+28.81%	34.55B
REVOLUTION MEDICINES, INC.	+1.09%	-1.47%	+260.51%	+468.77%	30.65B
IQVIA HOLDINGS INC.	+0.87%	+8.77%	+17.50%	-7.80%	28.97B
CELLTRION, INC.	+1.05%	-2.28%	+27.24%	+25.20%	27.29B
ASCENDIS PHARMA A/S	-0.43%	+3.91%	-	-	14.82B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-3.59%	-3.69%	+173.57%	+4,035.93%	13.51B
IONIS PHARMACEUTICALS, INC.	+0.60%	+0.50%	+135.06%	+113.07%	12.46B
EUROFINS SCIENTIFIC SE	+1.16%	+2.32%	+5.08%	-2.31%	12.13B
Average	+0.12%	+1.67%	+79.57%	+580.57%	24.19B
Weighted average by Cap.	+0.38%	+1.78%	+67.89%	+350.04%

Portola Pharmaceuticals, Inc. Stock

Equities

US7370101088

Biotechnology & Medical Research

Latest news : Portola Pharmaceuticals, Inc.

Press Releases: Portola Pharmaceuticals, Inc.

Other Biotechnology & Medical Research

Company Profile